DeutschNewstral
Article
jdsupra.com on 2020-03-10 20:28
FDA Requests Comments On Its Licensed Biological Products Database
Related news
- FDA Upgrades Its Database Of Licensed Biological Productsjdsupra.com
- Purple Book Database Of Biological Products Updated By FDAjdsupra.com
- FDA Releases Draft Guidance on Promotion of Biological Reference and Biosimilar Productsjdsupra.com
- FDA Requests Comment on Use of Dairy-Terms in Labeling of Plant-Based Food Productsjdsupra.com
- New Government Action Aims to Increase Competition among Biological Products: FDA and FTC Step Up Industry Pressurejdsupra.com
- FDA Finalizes New Definition of Biological Productjdsupra.com
- FDA Issues Final Definition for “Biological Product”jdsupra.com
- Summary of FDA Guidance on the Nonproprietary Naming of Biological Productsjdsupra.com
- FDA Issues Draft Guidance and Proposed Rule on the Nonproprietary Naming of Biological Productsjdsupra.com
- Guidance On Biological Product Transition Issued By FDAjdsupra.com
- FDA Issues Final Rule Amending The Definition Of “Biological Product”jdsupra.com
- FDA Will Facilitate Biological Product Development Against COVID-19jdsupra.com
- FDA Takes Aggressive Action Against CBD Productsjdsupra.com
- FDA Releases Consumer Update on CBD Productsjdsupra.com
- FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19jdsupra.com
- FDA Issues Draft Guidance On Biosimilar Licensure For Fewer Than All Conditions Licensed for Reference Productjdsupra.com
- FDA Releases Final Guidance: Transition of Previously Approved Drugs to Being "Deemed Licensed" Biologicsjdsupra.com
- FDA Final Guidance on Nonproprietary Names of Biological Productsjdsupra.com
- FDA Clarifies Premarket Path for Ecigarette Productsjdsupra.com
- FDA Announces Public Meeting on Regulation of Cultured Meat Productsjdsupra.com